Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CORBFNASDAQ:CSTLNASDAQ:PSNLNASDAQ:SBC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORBFGlobal Cord Blood$1.00$0.98$0.25▼$2.00$121.55M-0.66139,141 shsN/ACSTLCastle Biosciences$17.02$18.42$15.45▼$35.84$491.40M1.04411,117 shs343,692 shsPSNLPersonalis$5.06-1.7%$4.10$1.14▼$7.20$446.92M1.831.03 million shs972,268 shsSBCSBC Medical Group$5.11+5.6%$3.76$2.62▼$12.50$529.45M1.3560,669 shs90,509 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORBFGlobal Cord Blood0.00%0.00%-8.26%-1.96%-16.67%CSTLCastle Biosciences0.00%+6.71%+2.41%-15.78%-26.86%PSNLPersonalis-1.75%+10.24%+26.50%+22.22%+244.22%SBCSBC Medical Group+5.58%+9.89%+63.78%+55.79%+510,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ACSTLCastle Biosciences3.2307 of 5 stars3.55.00.00.03.32.50.0PSNLPersonalis3.7645 of 5 stars3.51.00.04.21.62.50.6SBCSBC Medical GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORBFGlobal Cord Blood 0.00N/AN/AN/ACSTLCastle Biosciences 3.00Buy$37.00117.39% UpsidePSNLPersonalis 3.00Buy$7.6751.52% UpsideSBCSBC Medical Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CORBF, CSTL, SBC, and PSNL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.004/10/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/28/2025CSTLCastle BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$30.003/17/2025PSNLPersonalisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORBFGlobal Cord Blood$196.12M0.62$0.71 per share1.40N/A∞CSTLCastle Biosciences$347.08M1.42N/AN/A$14.54 per share1.17PSNLPersonalis$85.69M5.22N/AN/A$2.64 per share1.92SBCSBC Medical Group$197.94M2.67$0.10 per share49.20($1.68) per share-3.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/ACSTLCastle Biosciences-$57.47M-$0.1985.10N/AN/A1.95%1.47%1.27%8/4/2025 (Estimated)PSNLPersonalis-$108.30M-$1.29N/AN/AN/A-104.52%-66.07%-41.34%8/6/2025 (Estimated)SBCSBC Medical Group$340KN/A0.000.91N/AN/A-11.59%-7.05%6/17/2025 (Estimated)Latest CORBF, CSTL, SBC, and PSNL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SBCSBC Medical Group$0.11$0.21+$0.10$0.21$51.52 million$47.33 million5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million3/28/2025Q4 2024SBCSBC Medical Group$0.17$0.18+$0.01$0.06$56.34 million$57.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORBFGlobal Cord BloodN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ASBCSBC Medical GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORBFGlobal Cord BloodN/AN/AN/ACSTLCastle Biosciences0.027.787.64PSNLPersonalisN/A4.684.44SBCSBC Medical Group0.062.792.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORBFGlobal Cord BloodN/ACSTLCastle Biosciences92.60%PSNLPersonalis61.91%SBCSBC Medical Group60.82%Insider OwnershipCompanyInsider OwnershipCORBFGlobal Cord Blood0.50%CSTLCastle Biosciences6.50%PSNLPersonalis3.80%SBCSBC Medical Group89.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableCSTLCastle Biosciences54028.87 million25.99 millionOptionablePSNLPersonalis40088.33 million67.75 millionOptionableSBCSBC Medical GroupN/A103.61 million37.19 millionN/ACORBF, CSTL, SBC, and PSNL HeadlinesRecent News About These CompaniesSBC Medical Group (NASDAQ:SBC) Shares Up 5.7% - Should You Buy?June 5 at 4:55 PM | marketbeat.comSBC Medical Group (NASDAQ:SBC) Trading Up 5.8% - Time to Buy?May 31, 2025 | marketbeat.comSBC Medical Group Holdings Incorporated Announces Participation in Upcoming Investor EventsMay 28, 2025 | quiverquant.comSBC Medical Announces Attendance at Upcoming Investor EventsMay 28, 2025 | globenewswire.comWhat is Zacks Small Cap's Estimate for SBC Q2 Earnings?May 24, 2025 | marketbeat.comQ3 EPS Estimates for SBC Medical Group Reduced by Sidoti CsrMay 23, 2025 | marketbeat.comSBC Medical Group Holdings First Quarter 2025 Earnings: EPS: US$0.21 (vs US$2.36 in 1Q 2024)May 17, 2025 | finance.yahoo.comIs It Too Late To Consider Buying SBC Medical Group Holdings Incorporated (NASDAQ:SBC)?May 16, 2025 | finance.yahoo.comSBC Medical Q1 Profit Rises 15 Pct Despite Revenue DipMay 16, 2025 | bernama.comSBC Medical Group Holdings Incorporated: SBC Medical Group Holdings Announces First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deSBC Medical Group Holdings Announces First Quarter 2025 Financial ResultsMay 15, 2025 | businesswire.comSBC Medical Group Holdings Announces Approval of Share Repurchase Program and Commencement of Share RepurchasesMay 15, 2025 | globenewswire.comWhy SBC Medical Group Holdings Incorporated’s (SBC) Stock Is Up 5.56%May 10, 2025 | aaii.comSBC Medical: Scalable Profits Undermined By Governance Overhang, Still Worth A LookMay 8, 2025 | seekingalpha.comSBC Medical Group Holdings, Inc. Purchases 5 BTCApril 14, 2025 | markets.businessinsider.comSBC Medical to Present at the Emerging Growth Conference on April 17, 2025April 9, 2025 | globenewswire.comSBC SBC Medical Group Holdings IncorporatedApril 5, 2025 | seekingalpha.comSBC: Recent Growth Measures Include Multi-Brand Strategy, Revised Pricing / Fee Structures, New Service OfferingsApril 2, 2025 | finance.yahoo.comSBC Medical Accelerates Multi-Brand Strategy with ‘SBC NEO Skin Clinic’ ExpansionMarch 31, 2025 | markets.businessinsider.comSBC Medical Accelerates Multi-Brand Strategy with ‘SBC NEO Skin Clinic' ExpansionMarch 31, 2025 | globenewswire.comWhy SBC Medical Group Holdings Incorporated’s (SBC) Stock Is Down 14.63%March 29, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCORBF, CSTL, SBC, and PSNL Company DescriptionsGlobal Cord Blood NYSE:CORBF$1.00 0.00 (0.00%) As of 06/4/2025Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Castle Biosciences NASDAQ:CSTL$17.02 0.00 (0.00%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$16.91 -0.11 (-0.67%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Personalis NASDAQ:PSNL$5.06 -0.09 (-1.75%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$4.96 -0.10 (-1.98%) As of 06/5/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.SBC Medical Group NASDAQ:SBC$5.11 +0.27 (+5.58%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$4.91 -0.20 (-3.99%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
